Does Inulin Lower TMAO? What Human Trials Actually Found

Inulin can change the gut microbiome without lowering trimethylamine N-oxide (TMAO), a metabolite often framed as a cardiovascular risk target. That is the central result of the best direct human trial: 10 g per day of inulin-type fructans for three months shifted a broad microbiome marker in peritoneal dialysis patients, yet plasma TMAO, fecal trimethylamine (TMA), and key TMA-producing microbial genes did not change.

This does not mean fiber is useless, nor does it settle whether TMAO causes cardiovascular disease in healthy people. It does mean that taking inulin specifically to lower TMAO asks more of the evidence than it can deliver.

A microbiome change is not the same as a TMAO change

TMAO comes from a two-step process. Gut microbes convert dietary compounds such as choline, carnitine, and betaine into TMA; the liver then converts TMA into TMAO. Because diet and microbes both shape that pathway, the proposed fix has seemed intuitive: feed beneficial microbes with prebiotic fiber and TMAO should fall.

In a double-blind crossover trial, Xiong et al. (2023) tested that idea in 22 people receiving peritoneal dialysis. Participants took 10 g daily of inulin-type fructans for three months and also received placebo in the alternate crossover period. This population has severely impaired renal clearance of TMAO, so a meaningful reduction in gut TMA production should be easier to detect in blood than it would be in people with normal kidney function.

The intervention did alter microbiome composition: the Firmicutes-to-Bacteroidetes ratio increased, with p=0.049. But the outcomes relevant to the proposed mechanism did not follow. The trial reported no significant reduction in fecal TMA, plasma TMAO, or the abundance of the microbial gene clusters CutC/D, CntA/B, and GrdH.

Those genes matter more than a phylum ratio. CutC/D helps microbes turn choline into TMA; CntA/B is involved in carnitine metabolism; GrdH participates in betaine reduction. The relevant TMA-producing genes occur across multiple bacterial phyla. A shift in the Firmicutes/Bacteroidetes ratio can therefore look biologically busy while leaving total TMA-producing capacity unchanged. The microbiome did not ignore the fiber. It simply did not make the functional change that the TMAO hypothesis requires.

Why the dialysis result carries weight—and where it stops

The crossover design gives each participant a chance to act as their own comparator, which can improve efficiency in a small study. The trial also measured more than plasma TMAO: it assessed fecal TMA and TMA-producing gene clusters. That makes the null result more informative than a study that measured a single blood marker at the end.

Still, 22 completers is a small sample. The available abstract does not report a formal power calculation, confidence interval, or effect estimate for TMAO. A small effect could therefore have gone undetected. The study supports a narrower conclusion: in this peritoneal-dialysis population, three months of 10 g daily inulin-type fructans did not significantly lower the measured TMAO-related outcomes.

It does not prove that inulin cannot affect TMAO in healthy adults. People with intact kidney function have lower baseline TMAO and clear it efficiently, while dialysis patients have a distinct clinical and dietary context. Those differences prevent a one-for-one extrapolation. They also do not create evidence that inulin works in healthier people; they create uncertainty.

A second fiber trial reached the same practical answer

The result does not stand alone. In hemodialysis patients, Kemp et al. (2022) found that resistant starch type 2 supplementation did not decrease plasma TMAO. Resistant starch type 2 is not inulin-type fructan, and hemodialysis is not peritoneal dialysis. That distinction matters. Yet the trials point in the same direction across two fiber interventions and two related high-TMAO populations: prebiotic fiber has not shown a TMAO-lowering effect there.

The published abstract available for the resistant-starch trial does not provide its sample size, effect estimate, p-values, or confidence intervals. It cannot support a precise comparison with the inulin trial. It does support the more limited observation that changing the fiber compound did not produce a reported fall in plasma TMAO.

Composition does not reliably predict function

The gap between a changed microbiome profile and unchanged TMAO fits evidence outside dialysis. In healthy adults, Ferrell et al. (2022) found that fecal microbiome composition did not predict plasma TMAO responses after a dietary challenge with TMAO precursors. This was an acute dietary-challenge finding, not a chronic fiber-supplementation trial, so it cannot answer whether long-term inulin changes TMAO in healthy adults.

It does challenge a common shortcut: treating a favorable-looking stool-community pattern as proof that TMA production has fallen. Microbiome composition is a map with poor resolution for this question. Gene abundance, enzyme activity, dietary precursor exposure, host metabolism, and renal clearance can all matter.

Dietary substrate also deserves more attention than many supplement pitches give it. In a randomized, controlled crossover feeding trial of healthy adults, Dhakal et al. (2022) found that 156 g per day of lean pork was noninferior to chicken for circulating TMAO response and microbiota-generated TMA; the study included 36 participants per protein condition, and the abstract reported a 97.5% confidence interval without providing its numerical bounds in the available excerpt. The finding does not show that animal protein is irrelevant to TMAO. It shows that, in this controlled comparison, lean pork did not produce a worse response than chicken.

Could other microbiome interventions work?

Possibly, but "microbiome-targeted" is too broad to function as a treatment category. A 2022 systematic review by Cantero et al. concluded that probiotic effects on TMAO reduction depend on the strain. That is a more plausible model than expecting any intervention that shifts community composition to lower TMAO.

A double-blind randomized trial in young healthy males by Chen et al. (2021) reported that a specific probiotic supplementation altered both gut microbiota composition and serum TMAO. This is encouraging for that intervention, not a license to generalize across probiotic products, ages, sexes, or doses. Probiotic labels often contain more confidence than strain-specific clinical evidence.

A more direct future strategy would target the microbial enzymes that make TMA. The inulin trial identifies CutC/D, CntA/B, and GrdH as relevant functional targets, but no human clinical trial in this evidence base shows that inhibiting those enzymes improves TMAO or clinical outcomes.

Does lowering TMAO improve cardiovascular health?

That question remains open in healthy adults. TMAO has disease-context evidence: Benson et al. (2023) linked higher TMAO with abdominal aortic aneurysm in a human cohort and reported inflammatory and apoptotic mechanisms in experimental work. The human component was observational, so it cannot establish that TMAO causes aneurysms or generalized atherosclerotic disease in people.

There is also an awkward dietary observation: fish consumption can raise plasma TMAO, while fish-rich dietary patterns are generally associated with favorable cardiovascular outcomes. That does not dismiss TMAO biology. It does make plasma TMAO a poor candidate for simple good-versus-bad storytelling. A biomarker can track risk in one setting, reflect food intake in another, and still fail as a stand-alone treatment target.

Verdict

Do not add inulin to a supplement routine specifically to lower TMAO. The direct randomized trial found that 10 g daily for three months changed a broad microbiome ratio but did not significantly reduce plasma TMAO, fecal TMA, or the relevant TMA-producing gene clusters in peritoneal-dialysis patients. A second dialysis trial of resistant starch type 2 also reported no plasma-TMAO reduction.

Inulin may still be reasonable for other evidence-based reasons, including fiber intake goals and tolerance-dependent digestive benefits. TMAO reduction is not one of the demonstrated reasons. If you are considering an intervention because of an elevated TMAO result, discuss the result in the context of kidney function, diet, medications, and overall cardiovascular risk with a clinician before treating one metabolite like a smoke alarm that identifies the fire.